Telix Pharmaceuticals Ltd
TLXDrugs in Pipeline
6
Phase 3 Programs
5
Upcoming Catalysts
3
Next Catalyst
This month
Market Overview
Stock performance and key metrics
3 upcoming, 1 past
68Ga-PSMA-11 Phase 3 Est. Readout
Primary completion for 68Ga-PSMA-11 trial (NCT07052214) in PCA
SourceTLX Earnings Report
EPS Est: $-0.01 | FQ end 2026-03
1 more catalyst beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Standard of Care
Metastatic Prostate Cancer
177Lu-TLX591
Metastatic Castration-resistant Prostate Cancer
68Ga-PSMA-11
Biochemical Recurrence of Malignant Neoplasm of Prostate
89Zr-TLX250 PET/CT
Clear Cell Renal Cell Carcinoma
Enzalutamide
Metastatic Castration-resistant Prostate Cancer
177Lu-DOTA-TLX591
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Standard of Care | Phase 3 | Metastatic Prostate Cancer | - | - |
177Lu-TLX591 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
68Ga-PSMA-11 | Phase 3 | Biochemical Recurrence of Malignant Neoplasm of Prostate | - | - |
89Zr-TLX250 PET/CT | Phase 3 | Clear Cell Renal Cell Carcinoma | - | - |
Enzalutamide | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
177Lu-DOTA-TLX591 | Phase 2 | Prostate Cancer | - | - |